Paasa Logo
Mabpharm Limited logo
2181HKSEMarket closedOpens 9:30am HKT

Mabpharm Limited

HK$0.50Last updated
-HK$0.02 (2.94%)Past day
Timezone
No price history for this range.

Mabpharm Limited (HKSE: 2181) is trading at HK$0.50, about ₹6 at today's HKD/INR rate, as of 25 Sep 2026, 3:59 AM ET, down 2.94% today. Indian residents can buy Mabpharm from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:HK$0.41
Previous close:HK$0.51
Volume:16.00K

Today's low

HK$0.41

Today's high

HK$0.51

52 week low

HK$0.31

52 week high

HK$0.81

2181 opened at HK$0.41, closed previously at HK$0.51, and has traded between HK$0.31 and HK$0.81 over the past 52 weeks.

About

Mabpharm Limited is a Chinese biopharmaceutical firm dedicated to the research, development, and manufacturing of innovative and biosimilar medications. Its therapeutic focus areas include allergic conditions, various cancers, and autoimmune disorders. The company boasts a robust pipeline, with several key products currently in advanced Phase III clinical trials. These include CMAB007, a recombinant humanized anti-IgE monoclonal antibody targeting asthma; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the initial treatment of metastatic colorectal cancer; CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody designed for moderate to severe active rheumatoid arthritis; and CMAB807, an agent developed for osteoporosis. Furthermore, Mabpharm is progressing various candidates through Phase I clinical development. Among these are CMAB819, aimed at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; CMAB807X, formulated for tumor bone metastasis; and CMAB809, which targets HER2 overexpressing breast cancer and metastatic gastric cancer. The preclinical pipeline is equally extensive, featuring CMAB810 for breast cancer; CMAB816, addressing periodic fever syndrome, lung cancer, and systemic juvenile idiopathic arthritis; and CMAB017, intended for KRAS wild-type colorectal cancer. Also in preclinical stages are biosimilar candidates such as CMAB015, an analog of secukinumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis; CMAB018, a mepolizumab biosimilar for asthma and eosinophilic granulomatous polyangiitis; and CMAB022, designed for various inflammatory conditions. Beyond its product development, Mabpharm provides a range of related services, including contract research and development, technical consultation, technology transfer, and specialized technical support for biological products, diagnostic and chemical biological reagents, and pharmaceutical compounds. Established in 2018, Mabpharm Limited is headquartered in Taizhou, People's Republic of China.

Country
CN
CEO
Hao Wang
Exchange listed on
HKSE
Industry
Biotechnology
Base currency
HKD
Full Time Employees
394
Sector
Healthcare
IPO date
31/05/2019

Key statistics

Avg. volume

225.22K

Market cap

HK$2.04B

P/E Ratio

20.64

Price-to-sales ratio

2.28

Enterprise value

CN¥1.96B

Free cash flow yield

1.02%

Debt-to-equity ratio

1.59

Return on equity

48.25%

ROIC

4.45%

Beta

0.61

Dividend yield

0.00%

Last dividend

HK$0.00

Financial overview

Revenue

CN¥629.37M

Earnings per share

CN¥0.01

Free cash flow

-CN¥23.22M

Net profit margin

11.09%

Gross margin

85.42%

EBITDA

CN¥62.91M

Revenue growth

143.73%

Similar securities

This is not an investment recommendation

How to buy Mabpharm from India

Indian residents can buy Mabpharm shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.

  3. Search for Mabpharm and place an order

    Find Mabpharm by name or by its ticker, 2181, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Mabpharm trades 7:00 am – 1:30 pm IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Mabpharm position in HKD and INR. Mabpharm pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Mabpharm from India

Trading and taxes when buying Mabpharm from India

Trading and limits

Trading hours
9:30 am – 4:00 pm HKT
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneMabpharm does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained

Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

FAQs

Can Indian residents buy Mabpharm stock?

Yes. Mabpharm (2181) has been listed on the Hong Kong Stock Exchange since 2019, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

How much does one Mabpharm share cost in rupees?

One Mabpharm share is HK$0.50 — about ₹6 at an HKD/INR rate of 12.25 on 28 Sep 2026. Both the Mabpharm price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Mabpharm from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

What is the minimum I can buy of Mabpharm?

Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.

How are gains on Mabpharm shares taxed in India?

Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Mabpharm price. Paasa issues a capital-gains statement for your return.

Does Mabpharm pay a dividend?

No. Mabpharm does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Mabpharm from India?

The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.

Is Mabpharm a Hong Kong SAR China company, and does that change how it is taxed?

Mabpharm trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Mabpharm trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.

Do I have to declare Mabpharm shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Mabpharm holding, its cost and its closing value.

How do I sell Mabpharm and bring the money back to India?

You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.